APA (7th ed.) Citation

CC, F., JA, C., AD, G., JW, L., RP, L., C, L., . . . JK, A. (2022). Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study. Multiple sclerosis (Houndmills, Basingstoke, England), 28(11), 1729. https://doi.org/10.1177/13524585221094239

Chicago Style (17th ed.) Citation

CC, Ford, et al. "Early Versus Delayed Treatment with Glatiramer Acetate: Analysis of Up to 27 years of Continuous Follow-up in a US Open-label Extension Study." Multiple Sclerosis (Houndmills, Basingstoke, England) 28, no. 11 (2022): 1729. https://doi.org/10.1177/13524585221094239.

MLA (9th ed.) Citation

CC, Ford, et al. "Early Versus Delayed Treatment with Glatiramer Acetate: Analysis of Up to 27 years of Continuous Follow-up in a US Open-label Extension Study." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 28, no. 11, 2022, p. 1729, https://doi.org/10.1177/13524585221094239.